Usually a double pivotal trial hit would be cause for celebration, but it might not be enough for Roche.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
The smoking-cessation drug, reformulated for nasal delivery, could be launched for dry eye, Oyster Point hopes.